Evidence map›Paper›PMID 34889894›Full record

ArticleCurrent issues in molecular biology2021

Strategy to Develop and Evaluate a Multiplex RT-ddPCR in Response to SARS-CoV-2 Genomic Evolution.

Laura A E Van Poelvoorde, Mathieu Gand, Marie-Alice Fraiture, Sigrid C J De Keersmaecker, Bavo Verhaegen, Koenraad Van Hoorde, Ann Brigitte Cay, Nadège Balmelle, Philippe Herman, Nancy Roosens

Open access · goldAbstract read
In one paragraph

Article in Current issues in molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Laura A E Van PoelvoordeTransversal Activities in Applied Genomics, Sciensano, 1050 Brussels, Belgium.ORCID 0000-0002-7442-5744
Mathieu GandTransversal Activities in Applied Genomics, Sciensano, 1050 Brussels, Belgium.ORCID 0000-0002-4424-2736
Marie-Alice FraitureTransversal Activities in Applied Genomics, Sciensano, 1050 Brussels, Belgium.
Sigrid C J De KeersmaeckerTransversal Activities in Applied Genomics, Sciensano, 1050 Brussels, Belgium.ORCID 0000-0003-4198-4133
Bavo VerhaegenFood Pathogens, Sciensano, 1050 Brussels, Belgium.
Koenraad Van HoordeFood Pathogens, Sciensano, 1050 Brussels, Belgium.
Ann Brigitte CayEnzootic, Vector-Borne and Bee Diseases, Sciensano, 1180 Brussels, Belgium.
Nadège BalmelleEnzootic, Vector-Borne and Bee Diseases, Sciensano, 1180 Brussels, Belgium.
Philippe HermanExpertise and Service Provision, Sciensano, 1050 Brussels, Belgium.ORCID 0000-0002-8938-0024
Nancy RoosensTransversal Activities in Applied Genomics, Sciensano, 1050 Brussels, Belgium.ORCID 0000-0001-9218-078X
Sciensano (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The worldwide emergence and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since 2019 has highlighted the importance of rapid and reliable diagnostic testing to prevent and control the viral transmission. However, inaccurate results may occur due to false negatives (FN) caused by polymorphisms or point mutations related to the virus evolution and compromise the accuracy of the diagnostic tests. Therefore, PCR-based SARS-CoV-2 diagnostics should be evaluated and evolve together with the rapidly increasing number of new variants appearing around the world. However, even by using a large collection of samples, laboratories are not able to test a representative collection of samples that deals with the same level of diversity that is continuously evolving worldwide. In the present study, we proposed a methodology based on an in silico and in vitro analysis. First, we used all information offered by available whole-genome sequencing data for SARS-CoV-2 for the selection of the two PCR assays targeting two different regions in the genome, and to monitor the possible impact of virus evolution on the specificity of the primers and probes of the PCR assays during and after the development of the assays. Besides this first essential in silico evaluation, a minimal set of testing was proposed to generate experimental evidence on the method performance, such as specificity, sensitivity and applicability. Therefore, a duplex reverse-transcription droplet digital PCR (RT-ddPCR) method was evaluated in silico by using 154 489 whole-genome sequences of SARS-CoV-2 strains that were representative for the circulating strains around the world. The RT-ddPCR platform was selected as it presented several advantages to detect and quantify SARS-CoV-2 RNA in clinical samples and wastewater. Next, the assays were successfully experimentally evaluated for their sensitivity and specificity. A preliminary evaluation of the applicability of the developed method was performed using both clinical and wastewater samples.

Indexed as

Evolution, MolecularCOVID-19COVID-19 Nucleic Acid TestingDiagnostic Tests, RoutineHumansRNA, ViralROC CurveSARS-CoV-2RNA, ViralCOVID-19droplet digital PCRmonitoringnext-generation sequencing datarespiratory samplesSARS-CoV-2wastewater

Identifiers

PMID34889894
PMCPMC8928932
OpenAlexW3211703106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.